Literature DB >> 27170610

Differential diagnosis of lung lesion in breast carcinoma: a metachronous neoplasm or metastasis?

Raja Naga Mahesh Maddala1, Karthik Udupa2, Joseph Thomas2, Kanthilatha Pai3.   

Abstract

A 34-year-old woman-a diagnosed case of pT1N1MO, stage IIa, estrogen and progesterone receptor positive (ER, PR) positive, Her2 negative carcinoma of the left breast-was managed with modified radical mastectomy and adjuvant chemotherapy. While planning for radiotherapy, she was found to have a well-defined enhancing lesion with spiculated margins in the superior segment of the right lower lobe along with a heterogeneously enhancing right hilar lymph node on CT. Histopathological evaluation of the lesion was suggestive of adenocarcinoma. The lesion was negative for ER, PR receptors, mammoglobin and gross cystic disease fluid protein. Thyroid transcription factor 1 (TTF-1) was positive, suggesting a primary lung adenocarcinoma rather than metastatic lesion from the breast. This case clearly signifies the importance of histopathological diagnosis of suspicious metastatic lesions in the setting of early breast cancer. We would also like to highlight the importance of TTF-1 in differentiating primary lung malignancy from metastasis. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27170610      PMCID: PMC4885342          DOI: 10.1136/bcr-2016-215125

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas?

Authors:  J S Reis-Filho; C Carrilho; C Valenti; D Leitão; C A Ribeiro; S G Ribeiro; F C Schmitt
Journal:  Pathol Res Pract       Date:  2000       Impact factor: 3.250

2.  Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma.

Authors:  Yue-Chiu Su; Yu-Chang Hsu; Chee-Yin Chai
Journal:  Kaohsiung J Med Sci       Date:  2006-01       Impact factor: 2.744

Review 3.  Breast cancer metastasis: markers and models.

Authors:  Britta Weigelt; Johannes L Peterse; Laura J van 't Veer
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

4.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

Authors:  P A Greenberg; G N Hortobagyi; T L Smith; L D Ziegler; D K Frye; A U Buzdar
Journal:  J Clin Oncol       Date:  1996-08       Impact factor: 44.544

5.  Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.

Authors:  Reuben J Broom; Patricia A Tang; Christine Simmons; Louise Bordeleau; Anna Marie Mulligan; Frances P O'Malley; Naomi Miller; Irene L Andrulis; Darren M Brenner; Mark J Clemons
Journal:  Anticancer Res       Date:  2009-05       Impact factor: 2.480

6.  HER-2/neu expression in primary and metastatic breast cancer.

Authors:  Elyse E Lower; Eleanor Glass; Robbin Blau; Stacy Harman
Journal:  Breast Cancer Res Treat       Date:  2008-02-14       Impact factor: 4.872

7.  Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas.

Authors:  Ming-Hua Luo; Yu-Hua Huang; Yun-Bi Ni; Julia Y S Tsang; Siu-Ki Chan; Mu-Min Shao; Gary M Tse
Journal:  Hum Pathol       Date:  2013-01-17       Impact factor: 3.466

8.  Predictors of early distant metastasis in women with breast cancer.

Authors:  Erick Sta Rosa Mendoza; Emmanuel Moreno; Priscilla Baetiong Caguioa
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-03       Impact factor: 4.553

9.  The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status.

Authors:  Sara J Schonfeld; Rochelle E Curtis; William F Anderson; Amy Berrington de González
Journal:  Cancer Causes Control       Date:  2012-08-24       Impact factor: 2.506

10.  The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas.

Authors:  Judit Moldvay; M Jackel; K Bogos; I Soltész; L Agócs; G Kovács; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.